NFKB1 and Miyoshi myopathy: The anti-tumor effect of bortezomib has been attributed to alterations of the NF-κB activity [31], accumulation of cell cycle proteins [30], a disturbed balance between pro- and anti-apoptotic proteins [32, 33], stimulation of endoplasmic reticulum stress [34], and impairment of the DNA repair pathway in the MM cells [35].